Exelixis (NASDAQ:EXEL) Price Target Raised to $42.00 - MarketBeat

18 hours ago · The firm has a market capitalization of $10.53 billion, a price-to-earnings ratio of 23.64, a PEG ratio of 0.88 and a beta of 0.53. Exelixis has a 1-year low of $20.01 and a 1-year high of $36.97. Exelixis (NASDAQ:EXEL - Get Free Report) last posted its quarterly earnings …

$42.00
OFF

Exelixis (NASDAQ:EXEL) Price Target Raised To $42.00 - MarketBeat

2 weeks from now

marketbeat.com

$29.00
OFF

Exelixis (NASDAQ:EXEL) Stock Price Expected To Rise, JMP …

2 weeks from now

18 hours ago · Finally, HC Wainwright raised their price target on Exelixis from $29.00 to $40.00 and gave the stock a "buy" rating in a research report on Friday, January 10th. One …

marketbeat.com

$37.13
OFF

15 Analysts Have This To Say About Exelixis - Exelixis (NASDAQ:EXEL)

2 weeks from now

1 day ago · In the assessment of 12-month price targets, analysts unveil insights for Exelixis, presenting an average target of $37.13, a high estimate of $42.00, and a low estimate of $29.00.

benzinga.com

$40.00
OFF

Exelixis (NASDAQ:EXEL) Stock, Analyst Ratings, Price Targets

2 weeks from now

6 days ago · The latest price target for Exelixis (NASDAQ:EXEL) was reported by HC Wainwright & Co. on January 10, 2025. The analyst firm set a price target for $40.00 expecting EXEL to …

benzinga.com

$34.95
OFF

What Is The Current Price Target And Forecast For Exelixis (EXEL)

2 weeks from now

6 days ago · Based on short-term price targets offered by 19 analysts, the average price target for Exelixis comes to $34.95. The forecasts range from a low of $26.00 to a high of $42.00. The …

zacks.com

$42
OFF

Exelixis Price Target Raised To $42 From $38 At Truist

2 weeks from now

1 day ago · Truist raised the firm’s price target on Exelixis (EXEL) to $42 from $38 and keeps a Buy rating on the shares after its positive Q4 pre-announcement. The firm views the stock …

businessinsider.com

$33.69
OFF

EXEL Stock Price Target | Exelixis Analyst Ratings

2 weeks from now

140 rows · This price target is based on 19 analysts offering 12 month price targets for Exelixis in the last 3 months. The average price target is $33.69, with a high forecast of $42.00 and a low …

pricetargets.com

$42
OFF

Exelixis Price Target Raised To $42 From $33 At Guggenheim

2 weeks from now

Jan 7, 2025 · Guggenheim analyst Michael Schmidt raised the firm’s price target on Exelixis (EXEL) to $42 from $33 and keeps a Buy rating on the shares. Late-stage pipeline asset …

nasdaq.com

$33.69
OFF

Exelixis (EXEL) Stock Forecast And Price Target 2025 - MarketBeat

2 weeks from now

6 days ago · According to the 19 analysts' twelve-month price targets for Exelixis, the average price target is $33.69. The highest price target for EXEL is $42.00, while the lowest price …

marketbeat.com

2%
OFF

Exelixis’ Price Target Raised At Truist, Shares Rise 2 Percent

2 weeks from now

36 minutes ago · Exelixis (NASDAQ:EXEL) shares rose more than 2% intra-day today after Truist Securities analysts increased their price target on the stock to $42, up from $38, while …

cweb.com

$42
OFF

Exelixis (EXEL) PT Raised To $42 At Guggenheim

2 weeks from now

(Updated - January 7, 2025 7:52 AM EST) Guggenheim analyst Michael W. Schmidt raised the price target on Exelixis (NASDAQ: EXEL) to $42.00 (from $33.00) while maintaining a Buy …

streetinsider.com

$32.44
OFF

Exelixis, Inc. (NASDAQ:EXEL) Receives $32.44 Consensus Price …

2 weeks from now

Jan 8, 2025 · EXEL has been the subject of several recent analyst reports. Guggenheim raised their price target on Exelixis from $33.00 to $42.00 and gave the company a “buy” rating in a …

defenseworld.net

$42.00
OFF

Guggenheim Boosts Exelixis (NASDAQ:EXEL) Price Target To $42.00

2 weeks from now

Jan 9, 2025 · Finally, BMO Capital Markets downgraded shares of Exelixis from an “outperform” rating to a “market perform” rating and increased their price target for the company from …

etfdailynews.com

$25.00
OFF

Barclays Sticks To Its Hold Rating For Exelixis (EXEL)

2 weeks from now

3 days ago · Barclays analyst Peter Lawson maintained a Hold rating on Exelixis (EXEL – Research Report) today and set a price target of $25.00. The company’s shares closed last …

businessinsider.com

$40.00
OFF

Exelixis (NASDAQ:EXEL) Price Target Raised To $40.00

2 weeks from now

3 days ago · Exelixis (NASDAQ:EXEL – Free Report) had its price target lifted by HC Wainwright from $29.00 to $40.00 in a report issued on Friday,Benzinga reports. The firm currently has a …

defenseworld.net

$38
OFF

Exelixis Price Target Raised To $38 From $34 At RBC Capital

2 weeks from now

Dec 30, 2024 · RBC Capital raised the firm’s price target on Exelixis (EXEL) to $38 from $34 and keeps an Outperform rating on the shares. Zanzalintinib stands out as Exelixis’ most clinically …

nasdaq.com

$30.00
OFF

Exelixis (NASDAQ:EXEL) Stock Price Expected To Rise, HC …

2 weeks from now

5 days ago · UBS Group began coverage on Exelixis in a research note on Thursday, September 19th. They set a "neutral" rating and a $30.00 price objective on the stock. Wells Fargo & …

marketbeat.com

$42.00
OFF

Guggenheim Boosts Exelixis (NASDAQ:EXEL) Price Target To $42.00

2 weeks from now

Jan 7, 2025 · Exelixis (NASDAQ:EXEL - Get Free ... TD Cowen boosted their target price on shares of Exelixis from $27.00 to $34.00 and gave the company a "buy" rating in a research …

marketbeat.com

$2.16
OFF

Exelixis Sets 2025 Guidance In Line With Estimates

2 weeks from now

2 days ago · Exelixis (NASDAQ:EXEL) expects $2.165B (consensus estimate: $2.17B) in total revenues for fiscal year 2024, with around ~$1.805B in net product revenues. The oncology …

seekingalpha.com

$42
OFF

Exelixis: Truist Raises Price Target Citing Increased Sales Potential

2 weeks from now

1 day ago · The brokerage raised PT to $42 from $38 while retaining a "Buy" rating. The analysts cited expanded sales potential for Cabometyx in treating neuroendocrine tumors (NET) as a …

investing.com

$37
OFF

Exelixis (EXEL) Stock Price, News & Analysis - MarketBeat

2 weeks from now

2 days ago · Exelixis price target raised to $37 from $36 at Piper Sandler. January 13 at 11:48 PM | markets.businessinsider.com. Exelixis (EXEL) Receives a Hold from Bank of America …

marketbeat.com

$37.00
OFF

Exelixis (NASDAQ:EXEL) Price Target Raised To $37.00 At

2 weeks from now

2 days ago · TD Cowen boosted their price target on Exelixis from $27.00 to $34.00 and gave the company a "buy" rating in a report on Monday, October 21st. Finally, Morgan Stanley boosted …

marketbeat.com

FAQs about Exelixis (NASDAQ:EXEL) Price Target Raised to $42.00 - MarketBeat Coupon?

Is Exelixis a good stock to invest in?

Exelixis has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, based on 10 buy ratings, 4 hold ratings, and no sell ratings. Exelixis has only been the subject of 4 research reports in the past 90 days. ...

Is Exelixis a good buy?

Exelixis, a biotechnology firm specializing in oncology treatments, continues to gain momentum with its flagship drug, Cabometyx, and its promising pipeline, Truist analysts said in a note. The brokerage raised PT to $42 from $38 while retaining a "Buy" rating. ...

Why have Truist analysts increased their price target for Exelixis Inc (Exel)?

Investing.com-- Truist analysts have increased their price target (PT) for Exelixis Inc (NASDAQ: EXEL), reflecting greater confidence in the company’s growth prospects. ...

Where can I buy shares of Exelixis?

Shares of EXEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. ...

What is the approval rating of Exelixis' CEO?

75 employees have rated Exelixis Chief Executive Officer Michael M. Morrissey on Glassdoor.com. Michael M. Morrissey has an approval rating of 79% among the company's employees. ...

How much will Exelixis make in 2024?

Exelixis (NASDAQ: EXEL) expects $2.165B (consensus estimate: $2.17B) in total revenues for fiscal year 2024, with around ~$1.805B in net product revenues. The oncology company also set financial guidance for 2025, projecting $2.15B - $2.25B (consensus estimate: $2.19B) in revenues for the year with $1.95B-$2.05B in net product revenues. ...